strong>Daiichi Sankyo Co. Ltd., of Tokyo, and its Plexxikon Inc. unit said The New England Journal of Medicine published clinical trial results demonstrating that investigational drug PLX3397, an oral targeted CSF-1R inhibitor, induced prolonged tumor regressions in most patients with tenosynovial giant cell tumor (TGCT), a rare, locally aggressive neoplasm of the joint or tendon sheath. Read More
Kyowa Hakko Kirin Co. Ltd., of Tokyo, and Bristol-Myers Squibb Co., of New York, said they entered a clinical trial collaboration agreement to conduct a phase I/II combination study with mogamulizumab, an anti-CCR4 antibody, and Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor. Read More
Genocea Biosciences Inc., of Cambridge, Mass., said it priced a public offering of about 3.8 million shares at $13 apiece for gross proceeds of $50 million. Read More
Winning orphan drug status for a second preclinical cancer therapy is "small but important progress" for Nanosmart Pharmaceuticals Inc., President James Smith told BioWorld Today. Read More
TAIPEI, Taiwan – Probably the most anticipated sessions at the recent BioBusiness Asia conference, part of BioTaiwan 2015, were panels featuring advice from partnering executives at firms famous for their external collaboration efforts, who described how a mix of traditional and nontraditional partnering models can bolster early research and maximize innovation. Read More
NEW DELHI – In a move that could cost India's generics industry more than $1 billion, the European Commission (EC) has banned 700 Indian generic drugs, based on flaws detected during inspections of clinical trials conducted by Hyderabad-based contract research organization GVK Biosciences Ltd. Read More
In one sense, the genetics of Huntington's disease are no mystery at all. The genetic cause – a DNA triplet expansion in the huntingtin gene – is clear. And it is also clear that those who have the mutation will inevitably get the disease. Read More
To protect their bottom line, companies have to do a lot of math. One of the factors they consider when pondering an acquisition, relocation or a home for their intellectual property (IP) is the ultimate tax bite. Read More
DUBLIN – Stem cell developer Tigenix NV is entering the cardiology arena through the acquisition of Madrid, Spain-based Coretherapix SL in a deal worth up to €266.7 million (US$291 million), the vast bulk of which is loaded toward the back end. Read More
Having received more than 60 comments on its 2014 interim guidance on subject matter eligibility, the Patent and Trademark Office (PTO) is releasing an update that includes a new set of examples and responds to several major themes raised during the comment period, according to a notice in Thursday's Federal Register. Read More
